Hims&Hers - Profitable in three years

Hims’ momentum looks strong, and hopefully, the Q4 results are as expected.

I was in the US this week, and my observation from TV advertising is that there are quite a lot of competitors. I didn’t specifically note down names, but ro.co advertised a GLP-1 product, Amazon generally advertised telemedicine, and 5-7 other companies advertised various blue pills or similar products delivered to home. I didn’t come across Hims’ ads. The sample isn’t very comprehensive, as I had an ESPN sports channel on for most of the time in the hotel.

8 Likes

The stock price has really surged. All signs certainly point to a strong Q4 result. At this rate, will it soon rise to the mid-cap index?

3 Likes

Hims perustaa pari uutta asiakas ohjelmaa edelleen kehittämään ja parantamaan asiakaskokemusta. Ensimmäisessä selvästi halutaan luoda yhteisö jossa voi jakaa asioita, ehkäpä keskustelupalstamaisesti,terveyteen liittyviä näkemyksiä ja kannustaa muita jäseniä.

Toinen taas kerää palautetta ja kehittää palvelua valittujen 15 asiakkaan kautta. Varmasti hyvä lisä. Nähtäväksi jää kehittyykö näistä jotain isompaa jatkossa vai jääkö kokeiluksi.

The Hims & Hers Health Collective is our new community-driven ambassador program that allows Hims & Hers customers to connect with and support other members on their health and wellness journeys. By sharing their stories with us, their community and our growing community, Health Collective members can be a voice of inspiration to others, be the first to learn about new products, and enjoy the benefits of community as they share their experiences and celebrate their progress and achievements together.

The Hims & Hers Community Member Council is an exclusive group of 15 Hims & Hers members hand-selected to help shape and influence the future of our platform. Their feedback and insights will help inform the innovation and development of products, services, and experiences across the Hims & Hers platform. This select group will collaborate directly with Hims & Hers teams and serve as the trusted voice and representatives of Hims & Hers customers everywhere.

16 Likes

Hims is one of my personal favorites for this year, but I expect a bumpy end to the week. The stock is still heavily shorted, and I believe those parties want to push the price down even with sheer willpower. Novo reports its earnings tomorrow and Lily in a couple of days; Hims has historically been very sensitive to the fluctuations of these two. Currently, we’re humming at ATH prices, so even a small uncertainty can bring a significant setback to the price.

As has been discussed here, I believe in a strong Q4 report and Q1 guidance, but at the same time, I also guess the price will take a hit before that. My positions will be cashed out today and bought back either cheaper or more expensively. Winners should be allowed to run, and here we’ll see if it was a wise move or not. A great company, but a volatile stock.

14 Likes

I’m thinking the same thing, and I just temporarily reduced my position size, even with the risk that it will continue to rise and I’ll have to buy back at a higher price.

I’ve been very much on top of this one and have been able to capitalize on its volatility. As you said, it has reacted sensitively to news, and it might still offer new buying/loading-up opportunities. This is one of the cornerstones of my portfolio, and it’s been unusual for me how much I’ve traded this stock compared to others which I mostly just buy and forget.

If a pullback occurs, it could dip to the $30-35 level, from which a new support level could form?

The above is pure speculation; do not base your own decisions on this under any circumstances.

2 Likes

IMG_6557

From Novo’s fresh report. Sounds like the shortage isn’t ending anytime soon.

34 Likes

Good morning, I’ve been mostly listening in this thread lately. Hims has indeed become more widely known to both customers and investors, with the Weight Loss category being the most significant driver. However, it’s been great to follow really high-quality comments and good discussion. To be honest, at some point I felt like it was just @karhulalainen and I talking, but luckily that has changed.

Hims has also progressed a lot, although it has been very predictable. The most important factors as an investment case, in my opinion, are 1) a huge market to eat into, which is also growing strongly, and 2) quality leadership.

For my part, this has meant the first tenbagger for one of my purchase batches at $4.2, although it was only a few hundred units. But it has also meant my portfolio growing to six figures by a long shot. Although there have been messages here about good buying and selling points, which some have undoubtedly used to make good returns, I personally learned from Tecnotree’s rise from 0.5€ → 1.7€ in 2021 that you shouldn’t trade rising prices if you don’t really know how. You just lose the best rising days, as they come so suddenly. So I’ve skipped it, luckily! I’ve just been holding. Another “mistake” I’ve made is not taking advantage of the market’s free lunch, i.e., diversification, but instead I’ve always been all-in on Hims, except for some small tests (Tecnotree, Fastly, StoneCo, Clear Secure) which I fortunately managed to sell before losses and put those into Hims as well.

Where is Hims now and where is it going? Is it time to take the money out and move on to the next one? Originally, I found Hims when I was looking for a tenbagger. All the ingredients seemed to be there, and now it has materialized. Currently, when I look at the company, I still see a huge market ahead, and as I previously estimated, growth indeed seems to be accelerating. Whether it’s permanent, I don’t know, but nothing indicates that growth would slow down to <50% y-o-y levels anytime soon. This combines the characteristics of a platform economy, service sales, and a product house. The drivers of growth are 1) the growth of the market under the current offering 2) growth caused by new product categories 3) geographical growth. At the same time, a future of tens of millions of subscribers and a 20% EDITDA margin are predicted. And these do not seem unrealistic in any way. Then, when I think about how the market could value such a company, I could guess off the top of my head that we are at least in the $100B class. And that again means a tenbagger compared to the current situation, so I intend to stay on board.

At the same time, the title of this thread has become outdated, and we should come up with something for it. How about sending me private suggestions for names, and we’ll make a poll in the thread?

53 Likes

https://x.com/himshouse/status/1887531844662399246

A non-profit organization is trying to block Hims’ ad at the Super Bowl. It feels like the FDA has bigger things to do right now (with Trump as the new president there) so these non-profits will fail and ultimately only give more visibility to the ad with this campaign.
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports - KFF Health News Before this, the non-profit in question protected American consumers from cheaper Canadian generic drugs.

10 Likes

Thanks @Construct-Destruct for your post. It contains many good lessons. I want to bring a few observations and lessons with HIMS to the readers. Here in this thread, HIMS was studied for a full 2 years in a bear market (autumn 2021 - autumn 2023). For two years, it was assured that it was a good company, that it was growing fast, and that profitability was improving. During those two years, the stock tripled from its lows and halved in six months. Why did it halve: because “smart money” listened carefully when HIMS announced in August 2023 that it was lowering its prices. Here in this thread, we, on the other hand, concluded that it was wise and traditional classic business management. “Smart money” sold and the price moved from $12 → below $6. And I remember when @Construct-Destruct said it was a good time to buy the dip :). At this point on 1.11.2023, 1 year and a quarter ago, we held onto our portfolios because we knew the stock. “Know what you own!”.

The US market is tough and tender, and a stock can be in a bear market for many years, even if the business is moving strongly forward. You just have to persevere stubbornly and not react to every rustle.

I myself have been “on a break” with HIMS once. It was that one May evening when Dudum made a politically charged tweet. I slept on it overnight, read his publications, clarified his family background, and wrote about it here in the thread. I concluded that the tweet was not political, but rather appreciative of humanity. Since then, there hasn’t been a weak moment. Even though those “smart money” scaremongers appear from time to time. An investor’s journey with HIMS is like a ghost train. Every now and then, someone pops out from behind a window saying “booooo”.

I agree with @Construct-Destruct. HIMS’s journey is just beginning or at least far from over. HIMS has its own patient information system. That is one cornerstone around which intelligence (AI), customer retention, and independence can be built. And in addition, there are all the other strengths, some of which have already been mentioned. That’s how Amazon also started with a brick-and-mortar store and then was an online bookstore and where did it end up. HIMS also has experience with brick-and-mortar :slight_smile: . I wish everyone perseverance with HIMS’s big stock price fluctuations.

47 Likes

Thanks @karhulalainen and @Construct-Destruct for the good discussion in the thread. Based on this, I originally became interested in Hims and started buying when the price was $3.2. It seemed so good that I dared to invest more than usual, and now it has gone quite nicely :blush: Last week, I sold a portion of the first batch of purchases for an amount equivalent to about three months’ salary. 5/6 remained in the portfolio, and I intend to hold them for quite a long time. Although the business still has significant growth potential (the story hasn’t even properly started yet), the rapid price increase is a bit concerning. Frankly, I find it difficult to come up with reasons why it would significantly increase from its current level. Of course, I don’t mean that it couldn’t happen; the market doesn’t always follow all rules of logic. But do you see any justifications for a continued price increase?

10 Likes

Well, there are all sorts of reasons for that:

  • Emotional reasons: momentum on its side, FOMO
  • Technical reasons: large short interest, some positive news for this, a strong Q4 and good guidance, then it’s a short squeeze and the price explodes
  • Fundamental reasons: The company’s MCAP is now just under 10 billion USD. If one considers what kind of FCF or profit HIMS is likely to make already this year, that’s really not a bad price for the company. One could write extensively about this fundamental side, but this, if anything, is a supportive factor for the price.
42 Likes

I would also add another driver for the stock price increase: according to some studies, generally speaking, when a company has made net profit for six (6) consecutive quarters, valuation multiples tend to increase – how much, then, depends on everything and especially on profitability, but Hims’ growth percentages and gross profits are quite strong, at least at this stage and in the near future as well.

(It’s a shame I don’t have sources for that research reference of mine, so take it with a grain of salt, and research the claim yourself, not an investment recommendation)

Have a good rest of your Thursday, everyone! :slight_smile:

8 Likes

Ultimately, the stock price follows the company’s success. As an investor, I look for precisely these profiles from a company. To me, the numbers say that everything is very well.

Below, I’ll include a few images that tell me HIMS is systematically moving in a good direction.

Free cash flow per share. This was the most important number table for me to be able to sit through the bottom. Free cash flow indicated that the company wasn’t consuming much cash and the direction was right.
image

Revenue growth is needed for the stock to rise.
image

Below is an image of net debt. And if the cash doesn’t melt away (even if the net result is heavily loss-making), then there’s no need to worry.
image

11 Likes

Thanks, those are good points and largely precisely the reasons why I myself am holding onto my shares tightly. I can’t comprehensively structure my thoughts on this right now, but at the same time, many of those points could also lead to the stock price turning downwards. We’ve recently had a taste of these big drops as the end of the GLP-1 shortage has been speculated: the reaction in relation to the business impacts has been quite over-the-top – does that indicate overvaluation of the stock? And even though a short squeeze is awaited, the number of shorts has remained high. In my opinion, the current stock price also has a lot of expectations loaded into the Q4 results. Even though it will probably be good, is it good enough for the market? Fundamentals and business growth are, of course, a good justification for the stock’s development, but can, for example, the last three months be justified by that either (1 month +50%, 3 months +75%)?

I don’t know, a bit of a non-post. Just pondering and trying to find reasons not to buy more, and being bearish with little success.

2 Likes

No, I believe it’s due to the market not (yet) understanding what HIMS is as a company. Surely many new owners who don’t know what they own. “Negative news” → panic → stock dips → buying opportunity.

These have all practically been nothingburgers, such a small part of the results comes from them. The Amazon news is a different matter in principle, but for those who believe in the case, that dip was also an excellent buying opportunity.

At some point in the future, similar opportunities might not be offered anymore. I agree with the comments above, it’s a risky game to trade rising stocks. If the position size is not full, the stock can run away very quickly. Dips can also be utilized by buying into a temporary overweight position if risk tolerance and cash reserves allow it.

Interesting times ahead, especially since it’s so heavily shorted.

7 Likes

image

The impact of the Super Bowl ad. An absolutely HUGE increase in Google searches. Time window: 1 year, if you don’t want to look more closely.

53 Likes

Apparently also growth in app download numbers based on app store ranking (positions 2 & 4).

https://x.com/himshouse/status/1888935157073072305?t=P0HAnsfWV4GSyutZcF8e7w&s=19

Screenshot_2025-02-10-15-08-22-56_0b2fce7a16bf2b728d6ffa28c8d60efb

Apparently, visibility doesn’t end with one expensive ad, but they are pushing proper multi-channel marketing in a new(?) way.

https://x.com/Kross_Roads/status/1888754519711871355?t=1fEbw04YHo_-ZF5jz3moug&s=19

Screenshot_2025-02-10-15-07-15-12_0b2fce7a16bf2b728d6ffa28c8d60efb

Shorts must be sweating.

41 Likes

Called it.

Joseph Carlson’s thoughts on Hims’s Super Bowl ad:

3 Likes

Hims & Hers’ valuation has already significantly exceeded analysts’ forecasts (average $29/share). Since the beginning of the year, it has taken a considerable lead, with the stock rising 85%. With a share price starting with a two (a value pulled out of Timo the magician’s hat), one could gladly jump in with a small tracking position. P/E is already galloping closer to 100 (forward ~90). Considerable expectations have been loaded into the pricing of Hims & Hers stock and the company. Whether the “sell the news” phenomenon will materialize in the near future, or if we’re heading for entirely new rounds to new valuation levels, remains to be seen. The scent of FOMO is already lingering in the air. Just summarizing my current thoughts here :wink:

Nimetön

8 Likes

HIMS is the largest position in my portfolio, but I’ve been involved even before these weight loss drug imitations (or what would be the correct translation?).
Am I the only one who is a bit worried about this whole part of HIMS’s business?

The warning text was displayed in such a small font and for only a couple of seconds.
kuva

kuva

Everything apparently went according to legal statutes, but I am a bit wary myself. IF some serious side effects occur and are linked to a HIMS product, then it would be a pretty big PR hit if the only defense is that small text in the advertisement. “But we did mention it!”

With the help of weight loss drugs, things have really gotten going and gained visibility, but the same opening also brings risks. Or does anyone have any reassuring insights on this?

4 Likes